Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
Demo Company
PURITAN MEDICAL

Blood Collection Device Minimizes Cellular DNA Release

By BiotechDaily International staff writers
Posted on 27 Aug 2013
Image: Cell-free DNA BCT tube (Photo courtesy of Streck, Inc.).
Image: Cell-free DNA BCT tube (Photo courtesy of Streck, Inc.).
Cell-free DNA (cfDNA) circulating in blood is currently used for noninvasive diagnostic and prognostic tests and minimizing background DNA is vital for detection of low abundance cfDNA.

A newly introduced blood collection device could reduce background levels of genomic DNA (gDNA) in plasma compared to standard tubes, when subjected to conditions that may occur during sample storage and shipping.

Scientists working for a commercial manufacturer took blood samples from healthy donors into tri-potassium ethylenediaminetetraacetic acid (K3EDTA) tubes and Cell-Free DNA BCT (BCT), which is a new collection device that contains a novel chemical cocktail. Samples were shaken or left unshaken to simulate shipping. In a shipping study, samples were shipped or not shipped. To assess temperature variations, samples were incubated at 6 °C, 22 °C, and 37 °C. In all cases, plasma was harvested by centrifugation and total plasma DNA (pDNA) assayed by quantitative real-time polymerase chain reaction (qPCR). The QIAamp Circulating Nucleic Acid Kit (Qiagen; Santa Clarita, CA, USA) was used for the extraction of pDNA.

The BCT tubes are manufactured by Streck, Inc., (Omaha, NE, USA) while the K3EDTA tubes were the BD Vacutainer, (Becton Dickinson; Franklin Lakes, NJ, USA). Shaking of blood drawn into K3EDTA tubes showed a significant increase in pDNA over 24 hours whereas no change was seen in Cell-Free DNA BCT tubes. Blood incubated at 6 °C, 22 °C, and 37 °C showed significant increases in pDNA isolated from K3EDTA tubes, while pDNA levels from Cell-Free DNA BCT remained stable over 14 days.

The novel stabilizing chemical cocktail prevents the release of gDNA into plasma post phlebotomy up to 14 days, avoiding labor-intensive requirements. Using this blood collection device, ex vivo storage at room temperature becomes possible, allowing flexibility for offsite blood drawn to be sent to centralized laboratories for downstream analysis of the cfDNA without preliminary centrifugations or cryopreservation.

The authors concluded that Cell-Free DNA BCT tubes prevent increases in background gDNA levels caused by temperature fluctuations or agitation that can occur during blood sample storage, shipping and processing. This novel blood-collection tube provides a method for obtaining high quality stabilized samples for rare DNA target detection and determining accurate cfDNA concentrations. The study was published on July 12, 2013, in the Journal of Clinical Laboratory Analysis.

Related Links:

Qiagen
Streck, Inc.
Becton Dickinson



Channels

Drug Discovery

view channel
Image: Cancer cells were treated with a control (left) and the overstimulating compound MCB-613 (right) (Photo courtesy of Dr. Lei Wang, Baylor University College of Medicine).

Drug Candidate Propels Cancer Cells into Fatal Overdrive

A candidate drug that destroys cancer cells by stimulating them to produce more proteins than the cells can actually process was shown to kill a wide variety of cancer cells in culture and to inhibit tumor... Read more

Lab Technologies

view channel
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major... Read more

Business

view channel

Innovative Microbial Diagnostics Developer Acquired by Biomedical Giant

A biotech company noted for its development of innovative products in the field of molecular microbiology diagnostics has been acquired by one of the world's largest biomedical corporations. GeneWEAVE BioSciences, Inc.(Los Gatos, CA, USA) and Roche (Basel, Switzerland) have announced that Roche will be purchasing the... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.